Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patients

Launay-Vacher, Vincent; Zimner-Rapuch, Sarah; Poulalhon, Nicolas; Fraisse, Thibault; Garrigue, Valérie; Gosselin, Morgane; Amet, Sabine; Janus, Nicolas; Deray, Gilbert

doi:10.1002/cncr.28709

Cited by 56 publications

(39 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The histological lesions suggest that there is a direct toxic effect of VMF on the renal tubules. Only one example of acute tubular necrosis under VMF was found in the literature, concerning a patient who underwent a similar kidney biopsy during VMF treatment [8]. This patient also took nonsteroid anti-inflammatory drugs, diuretics and had received iodinated contrast media.…”

Section: Discussionmentioning

confidence: 95%

“…The most common adverse effects are cutaneous reactions (skin rash, photosensitivity, hand-foot syndrome, alopecia, pruritus, squamous-cell carcinomas and second primary melanomas), pyrexia, arthralgia, asthenia, and liver function abnormalities [5]. However, renal toxicity has only been reported in several studies involving a small number of patients [6][7][8][9]. An improved understanding of renal toxicity of B-RAF inhibitors could help clinicians monitor patients now treated with a combination of B-RAF and mitogen-activated extracellular signalregulated protein kinase (MEK) inhibitors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma

Teuma

Perier‐Muzet

Pelletier

et al. 2016

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma

Teuma

Perier‐Muzet

Pelletier

et al. 2016

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…In a series of eight patients, Launay-Vacher et al found that the GFR decreased by 20-74 % and was probably related to concomitant use of other nephrotoxic agents [79]. They found that renal function improved in five patients, three after discontinuation of vemurafenib, and in two despite continuation of therapy.…”

Section: Vemurafenibmentioning

confidence: 95%

“…The commonly reported renal adverse events with vemurafenib include proteinuria and decreased glomerular filtration rate (GFR) [78,79]. In a series of eight patients, Launay-Vacher et al found that the GFR decreased by 20-74 % and was probably related to concomitant use of other nephrotoxic agents [79].…”

Section: Vemurafenibmentioning

confidence: 99%

Renal Toxicities of Targeted Therapies

et al. 2015

View full text Add to dashboard Cite

With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the array of toxicities associated with these agents be well-recognized and managed, especially since these toxicities are distinct from those seen with conventional cytotoxic agents. This review will focus on these renal toxicities from commonly used targeted agents. This review discusses the mechanisms of these side effects and management strategies. Anti-vascular endothelial growth factor (VEGF) agents including the monoclonal antibody bevacizumab, aflibercept (VEGF trap), and anti-VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs) all cause hypertension, whereas some of them result in proteinuria. Monoclonal antibodies against the human epidermal growth factor receptor (HER) family of receptors, such as cetuximab and panitumumab, cause electrolyte imbalances including hypomagnesemia and hypokalemia due to the direct nephrotoxic effect of the drug on renal tubules. Cetuximab may also result in renal tubular acidosis. The TKIs, imatinib and dasatinib, can result in acute or chronic renal failure. Rituximab, an anti-CD20 monoclonal antibody, can cause acute renal failure following initiation of therapy because of the onset of acute tumor lysis syndrome. Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, can result in proteinuria. Discerning the renal adverse effects resulting from these agents is essential for safe treatment strategies, particularly in those with pre-existing renal disease.

show abstract

“…Etiologicky dochází k poruše funkce ledvin pravděpo-dobně na úrovní tubulointersticiálního poškození. Kazuisticky byli u vemurafenibu popsané také případy akutního selhání ledvin vyžadující hemodialýzu [34].…”

Section: Ipilimumabunclassified

Cancer Treatment-induced Changes in Renal Function in Patients with Tumors – Update on Current Knowledge

Pokrivčák¹,

Poprach²

2018

Klin Onkol

View full text Add to dashboard Cite

Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno SouhrnVýchodiska: Abnormality funkce ledvin spojené s přítomností malignity bývají poměrně časté. Různě vyjádřená porucha renální funkce je přítomná přibližně u cca 60 % pa cientů s nádorem. Poškození ledvin může vznikat buď v důsledku přímého nebo nepřímého působení tumoru na ledviny a močové cesty. Systémová onkologická terapie může svůj negativní vliv na renální funkce uplatnit opět dvojím způsobem -přímým toxickým působením na strukturu ledvin a nepřímo v důsledku dehydratace nebo "tumor lysis syndromu". Od roku 2004 byla Food and Drug Administration schválena do klinického užití v terapii solidních nádorů řada potenciálně nefrotoxických chemoterapeutik, cílených léků a imunoterapeutik. Cíl: V rámci tohoto souhrnného článku přinášíme přehled nejnovějších informací týkajících se nefrotoxicity u nově používaných léků. Závěr: I přes nástup nových typů léků zahrnujících cílenou terapii a imunoterapii přetrvává riziko postižení ledvin. Mechanizmus vzniku je odlišný od klasické chemoterapie a většinou se jedná o toxicitu mírného nebo středního stupně. V klinických studiích nejsou ve většině případů zastoupení pa cienti s preexistující renální insuficiencí, a proto může být její vý-skyt v rutinní praxi vzhledem k vysoké prevalenci chronického onemocnění ledvin u onkologických pa cientů vyšší. Zhoršení renálních funkcí může významným způsobem ovlivnit strategii léčby, a proto je pečlivá monitorace renálních funkcí nedílnou součástí každé klinické kontroly. Klíčová slova renální selhání -toxicita -imunoterapie -chemoterapie SummaryBackground: Renal abnormalities associated with malignancy are common with renal impairment occurr ing in about 60% of patients with tumors. Kidney dis ease may occur as a result of direct or indirect effects of tumors on kidneys and the urinary tract. Systematic oncology treatment can affect renal function in two ways, via direct toxic effects on kidney structure and indirectly via dehydration or tumor lysis syndrome. Since 2004, the Food and Drug Administration has approved a number of potentially nephrotoxic chemotherapeutics, targeted drugs, and immunotherapeutics for the treatment of solid tumors. Aim: This article provides an overview of the latest information on the nephrotoxicity associated with the use of new drugs. Conclusion: Despite the development of new drug treatments, includ ing targeted ther apy and immunother apy, the risk of kidney involvement persists. The mechanisms of action of these new drugs are different from those of classical chemother apy, and their use is usually associated with only mild to moderate side effects. In clinical trials, patients with pre-exist ing renal insufficiency are not present in most cases. Deterioration of renal function may significantly affect the treatment strategy and therefore careful renal function monitor ing should be an integral part of each clinical trial.

show abstract

Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patients

Cited by 56 publications

References 7 publications

New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma

New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma

Renal Toxicities of Targeted Therapies

Cancer Treatment-induced Changes in Renal Function in Patients with Tumors – Update on Current Knowledge

Contact Info

Product

Resources

About